Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases, rheumatoid arthritis (RA), and antineutrophil cytoplasmic antibody-associated vasculitis. Treatment ILD, mainly based on immunosuppression, remains challenging. Rituximab (RTX), monoclonal antibody binding to CD20, is considered valuable therapeutic choice in cases refractory ILD. Here, we ...
